| Bioactivity | AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic[1]. |
| Invitro | AP-III-a4 (ENOblock) (0-10 μM; 24 h) inhibits HCT116 cell viability in a dose-dependent manner[1].AP-III-a4 directly binds to enolase and inhibits its activity[1].AP-III-a4 (0-10 μM; 24 or 48 h) inhibits cancer cell migration and invasion, induces cancer cell apoptosis[1].AP-III-a4 (10 μM; 24 h) can induce glucose uptake and inhibit phosphoenolpyruvate carboxykinase (PEPCK) expression in hepatocytes and kidney cells[1]. Cell Viability Assay[1] Cell Line: |
| Name | AP-III-a4 |
| CAS | 1177827-73-4 |
| Formula | C31H43FN8O3 |
| Molar Mass | 594.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
AP-III-a4
CAS: 1177827-73-4 F: C31H43FN8O3 W: 594.72
AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for th
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.